PDCD1 and colorectal carcinoma: We validated the main findings of the study in 176 additional regions from 13 patients with CRC (UH17–UH29, Supplementary Figure 1A) treated with anti-PD1 agents alone or in combinations with other immune checkpoint inhibitors as first-line therapy or in a chemorefractory setting (Supplementary Table 1).